COVID-19 Vaccines, Spike-Protein Persistence and “Detox”: What the Evidence Actually Shows (2026)

Updated: November 2026

An evidence-based review of mRNA persistence, residual DNA, extracellular vesicles, vaccine shedding, reported adverse effects and proposed spike-protein detoxification protocols.

Introduction: A debate that needs better evidence, not less scrutiny

The debate about COVID-19 vaccines has evolved. Beyond the initial questions about vaccine effectiveness and short-term adverse reactions, researchers are now investigating how long vaccine-derived mRNA and spike-related material can remain detectable in the body, whether residual manufacturing DNA presents a meaningful risk, and whether a small proportion of people experience persistent symptoms following vaccination.

Long COVID treatment 2026: guide to randomized clinical trial evidence from OneDayMD

Three related claims have become particularly prominent:

  1. Vaccine-derived spike protein and mRNA may persist much longer than initially expected.

  2. Residual plasmid DNA and extracellular vesicles may create additional biological effects that were not adequately considered.

  3. A proportion of people may benefit from interventions intended to reduce or clear persistent spike-related material.

These questions deserve scientific investigation. However, they should not be treated as though every proposed mechanism has already been demonstrated.

There is an important distinction between detecting a molecular fragment and demonstrating that it remains biologically active, causes disease or can be removed through a particular treatment.

This distinction is central to interpreting the available research.

The three articles reviewed for this update—The Un-Spiking of America, Three COVID Vaccines Were in the Vial, but Only One Was Tested, and The COVID Shot Was Three Vaccines, Not One & How We Can Heal From Them—raise issues worth examining. But several of their strongest conclusions need more careful qualification.

The most useful way to approach this subject is to separate four questions:

  • What was actually in the vaccine?

  • What evidence exists for persistence of vaccine-related material?

  • What evidence establishes harm or transmission to other people?

  • What treatments, if any, have been shown to improve outcomes?

1. How long can vaccine-derived mRNA and spike protein persist?

The original explanation of mRNA vaccination emphasized that the mRNA would be broken down after cells used it to produce the target antigen.

This is broadly consistent with the biology of RNA, which is susceptible to degradation by cellular enzymes called ribonucleases (RNases). However, the mRNA used in COVID-19 vaccines was chemically modified and packaged in lipid nanoparticles (LNPs), which protect it during delivery and influence its stability and cellular uptake.

It is therefore too simplistic to assume that every molecule disappears within a fixed number of hours or days.

Equally, it is incorrect to suggest that modified mRNA becomes permanently resistant to normal enzymatic degradation. Chemical modification and lipid packaging can affect persistence, but they do not make RNA indestructible.

What the human studies have found

Several studies have reported the detection of vaccine-related mRNA, spike protein or fragments in blood, lymph nodes and other biological samples after vaccination.

One particularly discussed investigation came from researchers associated with Yale University's LISTEN study.

The study, published as a preprint in 2025, examined 42 people reporting post-vaccination syndrome (PVS) and 22 healthy controls. The researchers reported differences in immune-cell profiles and detected circulating spike protein in a subset of participants, with some detectable measurements extending as far as 709 days after the last reported exposure.

This finding is worth investigating. It suggests that at least some people reporting persistent symptoms may have measurable immunological differences that warrant further study.

However, the study was small and cross-sectional. It does not establish how common this phenomenon is among vaccinated people, whether the detected material was responsible for symptoms, or whether all measured spike protein originated from vaccination rather than previous infection.

The researchers themselves emphasized that the relationship between persistent spike protein and chronic symptoms remains unresolved.

Source: Immunological and Antigenic Signatures Associated with Chronic Illnesses after COVID-19 Vaccination — medRxiv

A 2026 systematic review

A systematic review published in Future Journal of Pharmaceutical Sciences in February 2026 examined studies reporting the persistence of COVID-19 vaccine-related material in bodily fluids and tissues.

The review identified:

  • 13 studies examining bodily fluids.

  • 7 studies examining tissue or organ samples.

  • Reports of spike-related material in blood at intervals extending to 709 days.

  • Reports of vaccine-related mRNA in breast milk for up to seven days.

  • Reports of vaccine-related material in lymph nodes for up to approximately two months.

The authors also highlighted an important limitation: detecting a molecular fragment does not establish that it remains intact, biologically active or capable of causing clinical harm.

Many reported signals were close to the analytical detection limits. In several studies, the detected concentrations were substantially below those used in laboratory experiments that demonstrated biological effects.

The review also noted that the available studies were heterogeneous and that it did not formally assess risk of bias using a standardized tool. No meta-analysis was possible.

Its funding source should also be disclosed: the review received financial support from the Independent Medical Alliance, an organization associated with some of the researchers.

Source: The Persistence of COVID-19 Vaccine Artifacts in Bodily Fluids and Tissues: A Systematic Review — 2026

A different perspective from human tissue research

A 2026 study published in Scientific Reports examined vaccine-related mRNA and spike protein in mice and human post-mortem samples.

The researchers investigated tissue from 11 people who died within 14 days of receiving the Pfizer-BioNTech vaccine. The median age was 87.

They detected vaccine-related mRNA and spike protein in some samples from the injection-site muscle. Under the testing conditions used, neither was detected in the major organs examined.

The study is limited by its small sample, the short interval after vaccination and the use of post-mortem tissue. It cannot establish what happens in every vaccinated person over longer periods.

Nevertheless, it provides an important counterpoint to claims that vaccine-derived mRNA and spike protein routinely distribute widely and persist throughout multiple organs.

Source: Spatiotemporal Distribution of SARS-CoV-2 Vaccines and Vaccine-Related Proteins in Mice and Humans — Scientific Reports, 2026

What about reports of persistence lasting more than three years?

Some recent reviews and case reports cite detection of spike-related material, mRNA sequences or plasmid-associated DNA markers more than three years after vaccination.

These reports should not simply be dismissed. However, the longest reported intervals often come from isolated cases or studies using different analytical methods.

Three separate questions must be answered before interpreting such findings:

  1. Is the detected material demonstrably vaccine-derived?

  2. Is it an intact, functional molecule or a residual fragment?

  3. Does it produce a measurable biological effect associated with the patient's symptoms?

A positive molecular test does not automatically answer all three questions.

For example, a short RNA sequence may remain detectable even when the original mRNA molecule is fragmented and no longer capable of producing protein.

Likewise, detecting a spike peptide does not establish that intact spike protein is being continuously produced.

The current evidence supports further investigation into persistence in selected individuals. It does not demonstrate that most vaccinated people retain clinically harmful quantities of active spike protein for years.

2. Were there really three vaccines in one vial?

The phrase “three vaccines in one vial” is a provocative description, but it is not an accurate account of the vaccine's composition.

The discussion combines three different biological or manufacturing concepts:

  1. Modified mRNA.

  2. Residual plasmid DNA.

  3. Extracellular vesicles, including exosomes.

They should not be treated as three independently administered vaccines.

A. Modified mRNA: the intended active ingredient

The Pfizer-BioNTech and Moderna mRNA vaccines contain messenger RNA encoding a modified SARS-CoV-2 spike protein.

The mRNA includes chemical modifications, including N1-methylpseudouridine, intended to influence RNA stability and protein production.

The encoded spike protein also contains two proline substitutions, commonly called the 2P modifications, which stabilize the protein in its prefusion conformation.

The purpose is to allow cells to produce the target antigen and stimulate an immune response.

The presence of these modifications does not mean that the mRNA cannot be degraded. It means that the vaccine uses a delivery and molecular design intended to improve the effectiveness of antigen production.

B. Residual plasmid DNA: a legitimate manufacturing-quality question

Plasmid DNA is used as a template during the manufacture of mRNA vaccines.

The manufacturing process is intended to remove this DNA after transcription. Small residual quantities may remain in the finished product, which is why residual DNA is treated as a manufacturing impurity subject to quality specifications.

The presence of residual DNA is therefore not an invented concern. The important questions are how much remains, what sequences are present, how the DNA is packaged or fragmented, and whether exposure at the levels measured produces a meaningful biological risk.

The SV40 sequence question

Some Pfizer vaccine manufacturing plasmids contain an SV40 promoter/enhancer regulatory sequence.

It is important to distinguish this sequence from the SV40 virus itself.

The presence of a regulatory DNA sequence does not mean that an infectious SV40 virus was included in the vaccine. Nor does the presence of the sequence demonstrate that SV40 proteins are produced in vaccinated individuals.

In a December 2023 response to Florida's Surgeon General, the US Food and Drug Administration stated that no SV40 proteins are encoded for or present in the vaccines. The FDA also argued that the possibility of residual DNA fragments entering the nucleus and integrating into chromosomal DNA was implausible under the conditions described.

Source: FDA Response on Residual DNA and SV40 Sequences — December 14, 2023

However, regulatory conclusions should not be confused with a claim that every conceivable molecular mechanism has been experimentally excluded.

Critics have argued that certain plasmid sequences and lipid nanoparticle packaging could affect DNA uptake, degradation and intracellular distribution. These are hypotheses that require rigorous experimental testing.

The critical distinction is that the detection of residual DNA is not proof of genomic integration, cancer causation or heritable genetic alteration.

What do independent and regulatory tests show?

The Australian Therapeutic Goods Administration (TGA) published a report on residual DNA and endotoxin testing in 2024, updated in August 2025.

The TGA reported that it independently tested 28 batches of Pfizer and Moderna mRNA vaccines. All 28 batches met the World Health Organization's recommended residual DNA limit of up to 10 nanograms per dose using its validated quantitative PCR method.

The report also stated that 212 batches had been released through its batch-release process by October 2024.

This is relevant evidence, but it should not be overstated: testing 28 batches does not establish the precise residual DNA content of every batch distributed worldwide.

Source: TGA: Summary Report of Residual DNA and Endotoxin Testing

A further complication is that laboratories have not always agreed on the most appropriate methods for quantifying residual DNA.

A 2025 study by Achs and colleagues used several analytical methods to examine residual DNA in vaccine samples. A subsequent 2026 paper by McKernan, Speicher and Rose challenged aspects of that study's methodology, including primer design, detection limits and the potential underestimation of certain DNA fragments.

Source: Systematic Methodological Flaws in DNA Contamination Assessment of mRNA Vaccines — Oncotarget, 2026

This disagreement is a reason for better standardized, independent testing—not a reason to conclude that genomic integration or cancer causation has been established.

C. Extracellular vesicles and exosomes: not a third vaccine

Exosomes are small extracellular vesicles naturally released by cells. They participate in normal cell-to-cell communication and can transport proteins, lipids and RNA.

Some studies have reported spike-bearing extracellular vesicles following mRNA vaccination.

This is biologically interesting. It suggests that cellular communication pathways may transport vaccine-related proteins or other molecular material within the vaccinated person's body.

But this is not the same as administering a separate exosome vaccine.

Nor does it establish that exosomes carrying vaccine-derived mRNA or spike protein are being expelled in sufficient quantities through breath, saliva or sweat to affect other people.

The term “three vaccines” therefore blurs the distinction between an active vaccine ingredient, a manufacturing impurity and normal biological vesicles.

3. Process 1 versus Process 2: Was the commercial vaccine different from the trial product?

Another issue raised in the articles is the change in Pfizer's manufacturing process.

During development, Pfizer used a process commonly described as Process 1. As production was scaled up, the company adopted Process 2, which used a different method of generating the DNA template for mRNA production.

Broadly, Process 1 used a PCR-based DNA template, while Process 2 relied on plasmid DNA produced in bacterial cultures.

This manufacturing change is real and deserves transparent discussion.

The important questions include:

  • Were the changes adequately characterized?

  • Were residual DNA and other impurities appropriately controlled?

  • Was mRNA integrity maintained?

  • Were the commercial batches sufficiently comparable to the clinical-trial material?

It is fair to ask whether public disclosure of manufacturing comparability was sufficiently detailed.

However, it is an overstatement to conclude that the commercial product received no regulatory quality assessment.

The UK Medicines and Healthcare products Regulatory Agency's public assessment report describes batch-specific quality review, comparison of batch-release results with clinically qualified ranges from clinical-trial batches, and independent batch testing before deployment.

Source: MHRA: Pfizer-BioNTech COVID-19 Vaccine Public Assessment Report

A regulatory comparability assessment is not the same thing as conducting another large Phase 3 clinical trial of every manufacturing change.

The distinction matters: the manufacturing changes warrant scrutiny, but the existence of a different manufacturing process does not, by itself, prove that the marketed vaccine was an untested or fundamentally different vaccine.

4. Interpreting the V-safe 7.7% figure

The November 2026 article highlights a figure of approximately 7.7% from the CDC's V-safe monitoring system.

According to the analysis cited by the article, 782,913 of approximately 10.1 million V-safe participants reported a health event requiring medical attention, emergency-room intervention and/or hospitalization.

This is an important example of why the precise definition of an outcome matters.

The 7.7% figure does not mean that 7.7% of participants were hospitalized because of vaccination.

V-safe collected self-reported health information. The 7.7% figure included any reported medical attention, potentially including a telehealth consultation, and covered a period of up to one year after vaccination. It did not establish that every reported event was caused by the vaccine.

FactCheck.org also noted that published analyses of early V-safe data reported much lower rates of medical care during the first week following vaccination. A CDC spokesperson cited first-week medical-care rates of approximately 1–3%, depending on age group, vaccine and dose.

These figures are not directly interchangeable because they examine different time periods and outcome definitions.

Source: FactCheck.org: Posts Distort Misleading Analysis of COVID-19 Vaccine Safety Data

This does not mean that people reporting significant adverse reactions should be ignored. It means that passive reports, voluntary surveys and active clinical surveillance must be interpreted according to their design.

What about the claim that 1,203 Pfizer trial participants disappeared?

The November 2026 article refers to a report alleging that 1,203 participants were “lost to randomization” in Pfizer's pivotal trial.

The cited OpenVAET report does identify discrepancies between two sets of investigator files and argues that these differences require investigation.

However, there is an important distinction between a court ordering the release of trial documents and a court ordering or validating an independent audit.

The Texas court proceedings cited by the report concerned the release of regulatory documents. The court did not make a judicial finding that 1,203 participants had been deliberately deleted from the trial.

The numerical discrepancy is an allegation made by the report's authors and should be investigated and reconciled against the underlying records before being presented as established evidence of deliberate data manipulation.

There were also serious allegations about trial conduct at Ventavia, a contract research organization involved in several Pfizer trial sites, which were reported by the BMJ.

Those concerns deserve proper scrutiny. However, documented problems at specific trial sites do not automatically establish wholesale falsification across the entire trial.

Sources:

5. Can vaccinated people transmit spike protein or vaccine material to others?

The term vaccine shedding is often used imprecisely.

Traditional viral shedding refers to the release of infectious virus particles from an infected person. This is not how an mRNA vaccine works.

An mRNA vaccine does not contain the complete coronavirus genome or the machinery needed to reproduce an infectious SARS-CoV-2 virus.

A different question is whether small amounts of vaccine-derived molecular material could leave cells or enter biological secretions.

This is an area of active investigation.

What do exosome studies demonstrate?

Studies have reported extracellular vesicles containing spike-related material after vaccination.

Such findings support the possibility of intracellular and intercellular transport within the vaccinated person.

They do not establish that another person can acquire a biologically meaningful dose through ordinary contact.

The distinction between transport within the body and transmission between people is essential.

What about breast milk?

Small studies have reported the detection of trace vaccine-related mRNA in breast milk shortly after vaccination.

The 2026 systematic review identified reports of mRNA detection in breast milk for up to seven days.

This is a finding worth understanding, but it does not establish that breast milk becomes a source of clinically significant vaccine exposure to infants. Detection of a small amount of RNA does not demonstrate that it remains intact, enters infant cells, produces spike protein or causes harm.

Nor can findings in breast milk be used as evidence that vaccine components are being transmitted through sweat or exhaled breath.

The October 2026 shedding preprint

An October 26, 2026 preprint by Catanzaro, Hulscher and McCullough examined proposed mechanisms of internal molecular dissemination and possible human-to-human transfer.

Importantly, the authors acknowledged that no published study had directly demonstrated transfer of vaccine-derived spike protein, mRNA or plasmid-associated DNA between people through respiratory emissions, saliva, sweat or other non-milk secretions.

This is a significant qualification.

The paper proposes biological pathways that might be investigated. It does not demonstrate that ordinary proximity to a vaccinated person exposes another person to a clinically significant amount of vaccine material.

Source: mRNA Vaccine Shedding: Internal Transcriptional Dissemination and Potential Human-to-Human Transfer — Zenodo, October 26, 2026

The menstrual-abnormality survey

A frequently cited 2024 paper examined reported menstrual abnormalities and proximity to vaccinated individuals.

The study included 6,049 respondents, with a subgroup of 3,390 reporting no vaccination, COVID-19 symptoms or positive COVID-19 test.

However, an important methodological issue is that the online survey recruited women who were already experiencing menstrual abnormalities. Participants were recruited through crowdsourcing and social media.

This creates substantial selection and recall-bias concerns.

The study can generate hypotheses about possible associations, but it cannot establish the prevalence of menstrual abnormalities among the general unvaccinated population or prove that vaccine material was transmitted from vaccinated people.

It also did not demonstrate that spike protein, mRNA or exosomes were transferred through close contact.

Source: Menstrual Abnormalities Strongly Associated with Proximity to COVID-19 Vaccinated Individuals — 2024

As of November 21, 2026, the evidence does not establish clinically significant person-to-person transmission of vaccine-derived spike protein or mRNA through everyday contact, breathing or sweat.

6. Post-vaccination syndrome: a legitimate research question

The absence of proof for every proposed mechanism should not be used to dismiss people who report persistent symptoms after vaccination.

Some individuals report prolonged health problems beginning shortly after receiving a COVID-19 vaccine. Symptoms described in research and patient reports include:

  • Persistent fatigue and exercise intolerance.

  • Cognitive difficulties and brain fog.

  • Palpitations and increased heart rate.

  • Neuropathic symptoms, tingling and numbness.

  • Sleep disturbances.

  • Dizziness and symptoms associated with autonomic dysfunction.

These symptoms are real experiences and deserve appropriate clinical assessment.

Researchers have begun examining whether a subgroup of affected individuals has distinctive immune, inflammatory or neurological characteristics.

The Yale LISTEN work is one example. Other studies have examined immune-cell profiles, inflammatory markers, antibody patterns and possible similarities between post-vaccination syndrome and Long COVID.

However, there is not yet a universally accepted diagnostic definition or validated biomarker for post-vaccination syndrome.

It is also important to distinguish temporal association from causation. A symptom that begins after vaccination deserves investigation, but it does not automatically identify the mechanism responsible.

Potential alternative or overlapping explanations include previous SARS-CoV-2 infection, cardiovascular disease, autonomic dysfunction, endocrine abnormalities, anemia, autoimmune conditions, medication effects and other post-infectious syndromes.

The appropriate response is neither automatic dismissal nor automatic attribution to spike protein.

It is careful clinical evaluation and continued research.

7. Recognized vaccine adverse effects should not be overlooked

COVID-19 vaccines have been associated with rare but recognized serious adverse events.

Myocarditis and pericarditis are among the best-established concerns following mRNA vaccination.

The risk has been most frequently observed in adolescent and young adult males, particularly within seven days after the second mRNA vaccine dose. Cases have also been reported in females and after other doses.

The CDC's updated September 2026 guidance continues to identify myocarditis and pericarditis as rare adverse events following COVID-19 vaccination.

Other recognized serious adverse events vary by vaccine platform and include anaphylaxis and, for certain vaccine types, thrombosis with thrombocytopenia syndrome and Guillain-Barré syndrome.

Most common post-vaccination reactions, such as fever, fatigue, headache and muscle pain, are mild to moderate and resolve within several days.

Source: CDC: Safety Considerations for COVID-19 Vaccines — September 23, 2026

These established safety signals should be discussed separately from broader hypotheses about persistent spike protein.

A documented adverse event does not prove every proposed mechanism, just as uncertainty about a mechanism does not invalidate a patient's symptoms.

8. Can spike protein be measured in blood tests?

Some discussions of spike detoxification use commercial antibody tests and interpret a numerical result as a measure of how much spike protein remains in a person's body.

This is an important misunderstanding.

An anti-spike antibody test measures the antibodies produced by the immune system in response to spike protein exposure.

It does not directly measure circulating spike antigen.

A high antibody result therefore does not establish that a person has a high concentration of free spike protein in the blood, nor does a lower result prove that spike protein has been removed.

Antibodies may be produced following either SARS-CoV-2 infection or vaccination. Their concentrations can change over time, and results depend on the particular test used.

The FDA specifically cautions that SARS-CoV-2 antibody tests cannot establish whether someone has an active infection or whether they are protected from future infection.

Source: FDA: Antibody (Serology) Testing for COVID-19

Consequently, numerical thresholds such as 1,000 binding antibody units should not be used as validated cut-offs for determining whether a person is “spike-free” or requires detoxification.

A clinically useful test would need to measure the relevant antigen or molecular marker directly, distinguish vaccine-derived material from infection-derived material, and demonstrate that the result has diagnostic or prognostic value.

At present, no widely validated clinical test can establish a person's total tissue spike burden or determine whether a proposed detoxification protocol has successfully cleared it.

9. Does a spike-protein detoxification protocol work?

One of the practical recommendations in The Un-Spiking of America is a protocol based on nattokinase, bromelain and curcumin, together with measures intended to promote elimination through sweating.

These interventions have attracted interest because of laboratory findings involving fibrin, inflammation, proteolytic activity and other biological pathways.

However, a plausible laboratory mechanism is not the same as demonstrated clinical effectiveness.

Nattokinase

Nattokinase is an enzyme derived from fermented soybeans. Laboratory and preliminary research has explored its fibrinolytic properties and possible effects on blood clotting.

These observations do not establish that nattokinase clears vaccine-derived spike protein from human tissues or improves post-vaccination syndrome.

It may also increase bleeding risk, particularly when combined with anticoagulants or antiplatelet medications.

Bromelain

Bromelain is a mixture of enzymes extracted from pineapple.

It has been investigated for anti-inflammatory and proteolytic properties. Nevertheless, there is insufficient clinical evidence that oral bromelain can reach relevant tissues at effective concentrations and remove persistent vaccine-derived spike protein.

It may also interact with medications and increase bleeding risk.

Curcumin

Curcumin, a compound found in turmeric, has been studied for anti-inflammatory and antioxidant effects.

Its bioavailability varies substantially between formulations. There is no established clinical evidence that curcumin eliminates vaccine-derived spike protein from the body.

Sweating and sauna use

Sweating is an important physiological mechanism for regulating body temperature. However, the presence of a substance in one biological secretion does not establish that it is removed through another.

Detection of vaccine-related RNA in breast milk or molecular material in skin samples does not demonstrate that sweating is a proven method of clearing spike protein.

There are no established clinical protocols showing that sauna use or induced sweating removes clinically relevant quantities of vaccine-derived spike material.

What does the evidence say about the overall protocol?

The 2023 paper proposing a spike-protein detoxification protocol acknowledged the absence of large, prospective, randomized, placebo-controlled trials establishing its effectiveness.

That limitation remains important.

There is currently no established clinical evidence that a combination of nattokinase, bromelain, curcumin or sauna therapy reliably clears persistent vaccine-derived spike protein or reverses post-vaccination syndrome.

Source: Potential Health Benefits of Nattokinase and a Proposed COVID-19 Vaccine Detoxification Protocol — 2023

This does not mean that every ingredient is without biological activity. It means that the specific treatment claim has not been clinically established.

People taking anticoagulants, antiplatelet medications or other drugs that affect bleeding should be particularly cautious about combining them with high-dose nattokinase or bromelain. Supplement use should be discussed with a qualified healthcare professional.

A treatment should not be described as a proven detoxification protocol until controlled clinical studies demonstrate that it improves meaningful health outcomes.

10. What should people with persistent symptoms do?

People who develop persistent symptoms after COVID-19 vaccination deserve to be taken seriously.

The most useful starting point is to identify the actual clinical problem rather than assume that every symptom is caused by one circulating molecule.

A reasonable approach includes:

  1. Document the timeline. Record when symptoms began, their progression, previous infections, vaccination dates, medications and relevant medical history.

  2. Investigate specific symptoms. Depending on the presentation, clinical assessment may include cardiovascular evaluation, blood tests, neurological examination, thyroid testing, evaluation for anemia, or assessment for autonomic dysfunction.

  3. Treat established diagnoses. Management should be guided by objective findings and the patient's clinical condition rather than an unvalidated assumption of persistent spike toxicity.

  4. Report suspected adverse reactions. Patients and clinicians should use the relevant national pharmacovigilance reporting system. Reporting is important even when causality has not yet been established.

  5. Avoid unproven high-dose protocols. Supplements marketed for spike removal should not replace appropriate medical assessment or established treatment.

New chest pain, severe shortness of breath, fainting, sudden neurological symptoms or signs of a possible blood clot warrant urgent medical assessment.

11. What research is still needed?

The debate would benefit from better-designed studies rather than further arguments based on isolated observations.

Several research priorities stand out.

A. Longitudinal studies of spike and mRNA persistence

Researchers need to follow adequately sized cohorts over time, using validated assays and appropriate control groups.

The studies should distinguish:

  • Vaccine-derived spike from infection-derived spike.

  • Intact mRNA from fragmented RNA.

  • Full-length spike protein from isolated peptides.

  • Transient molecular detection from continued biological activity.

B. Better biodistribution and tissue studies

More research is needed to understand the duration and location of vaccine-related material in human tissues.

Studies should include appropriate controls and clearly document the timing of vaccination, infection history and sample collection.

C. Independent residual DNA testing

Residual DNA testing should be independently replicated across laboratories, vaccine formulations and manufacturing batches.

Analytical methods should be standardized, validated and transparent about detection limits, fragment-size bias and possible interference from RNA-DNA hybrids.

The objective should be to establish what is actually present in commercial products, rather than relying entirely on either manufacturer or activist testing.

D. Research into post-vaccination syndrome

Large prospective studies should investigate people reporting persistent symptoms after vaccination.

Useful research would include:

  • Well-defined clinical diagnostic criteria.

  • Appropriate vaccinated and infection-matched control groups.

  • Immune and inflammatory profiling.

  • Cardiovascular and autonomic assessments.

  • Longitudinal symptom tracking.

  • Reproducible biomarkers.

  • Trials of interventions with clinically meaningful outcomes.

E. Controlled clinical trials of proposed treatments

Nattokinase, bromelain, curcumin, antihistamines, immunomodulatory treatments and other proposed interventions should be evaluated through properly designed clinical trials where there is a credible scientific rationale.

Trials should measure patient-important outcomes, not merely changes in antibody concentrations or unvalidated laboratory markers.

Conclusion: Acknowledge the questions, but follow the evidence

The COVID-19 vaccine debate should not be reduced to two opposing positions: that all concerns are misinformation, or that every unexplained illness following vaccination is proof of persistent spike toxicity.

There are legitimate questions about mRNA kinetics, vaccine biodistribution, residual DNA impurities, manufacturing changes and rare adverse events.

Research has reported vaccine-related molecular material persisting longer than the original simplified explanations suggested. A subset of people reporting post-vaccination syndrome has also demonstrated measurable immunological differences that warrant further investigation.

These findings deserve independent replication and clinical follow-up.

At the same time, the current evidence does not establish that most vaccinated people retain clinically toxic quantities of spike protein for years, that residual DNA has been shown to integrate into the human genome, that vaccinated people transmit spike protein through everyday contact, or that nattokinase, bromelain, curcumin and sweating constitute a proven spike-removal treatment.

The distinction between molecular detection, biological activity and clinical harm is not semantic. It is fundamental to sound medical research.

The priority should be transparent independent testing, better long-term studies, proper recognition of adverse events and randomized clinical trials of treatments proposed for people with persistent symptoms.

Patients deserve to be heard. Scientific claims deserve to be tested. And treatment recommendations should be supported by evidence, not simply by plausible mechanisms or compelling anecdotes.


Medical disclaimer: This article is for educational purposes and is not individual medical advice. It does not recommend stopping prescribed treatment, avoiding indicated medical care or starting high-dose supplements without professional guidance. Decisions about vaccination and treatment should take account of individual health risks and current clinical guidance. 

Comments

Popular posts from this blog

Dr Peter McCullough: How to Detox Spike Protein from Body (2026 Update)

Dr Peter McCullough: How to Measure Your Spike Protein Antibody (2026)

Dr. Peter McCullough's Spike Protein Detox Protocol: Base Spike Detox Explained (2026)

Long COVID Treatment 2026: The Complete Evidence Guide

Dr Peter McCullough: Povidone Iodine, Oral and Nasal Hygiene (2026)

IMA/FLCCC I-Recover Protocol: Post Vaccine Treatment Protocol (2026 Evidence Review)

Fact Check: Unpacking the Spike Protein Debate (2026)

Nattokinase: What 46 Years of Research Actually Shows

FLCCC I-CARE Treatment Protocol for Flu and RSV: What the Evidence Shows (2026–27 Update)

How We Can Heal From the COVID-19 Vaccines?: I-Recover Protocol and McCullough Base Spike Detox — Definitive 2026 Guide

Labels

Show more